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Abstract
Epidermolysis bullosa (EB) pruriginosa is a subtype of dominant dystrophic epidermolysis 
bullosa (DDEB), characterized by severe pruritus and blistering localized to the extensor 
surface of the extremities.  EB pruriginosa exhibits extensive clinical  heterogeneity with 
variable expressivity and delayed age of onset.  Mutations in the COL7A1 gene, especially 
in glycine residues within of Gly-X-Y repeats, have been shown to cause this form of 
DDEB.  Here, we report a novel COL7A1 mutation in a Taiwanese pedigree with EB 
pruriginosa.  Using polymerase chain reaction amplification and direct sequence analysis, 
we have identified a G-to-T transversion at nucleotide 7097 within exon 92 of COL7A1, 
converting a glycine residue to valine (G2366V).  The mutation resides within a 
consecutive, uninterrupted 17 Gly-X-Y of the triple-helical domain of type VII collagen.  
Interestingly, the proband in our family also displayed elevated IgE levels, previously 
reported in some patients with this disorder.  Our finding further implicates COL7A1 
mutation in the pathogenesis of EB pruriginosa and underscores the heterogeneous clinical 
symptoms of glycine mutations in DDEB.
Report
Dystrophic epidermolysis bullosa (DEB) is a collection of hereditary bullous 
disorders characterized by blistering, scarring, and nail dystrophy.1  The fragility is 
attributed to scarcity, or even the complete absence of anchoring fibrils composed mainly of 
type VII collagen.1  Autosomal dominant and recessive inheritance patterns, as well as 
sporadic cases of DEB have all been described.2-4  To date, several hundred pathogenetic 
mutations within the collagenous and noncollagenous domains of type VII collagen gene 
(COL7A1)  have been identified in different forms of DEB.5-12   One subtype of dominant 
dystrophic epidermolysis bullosa (DDEB) is EB pruriginosa associated with intense 
pruritus and nodular prurigo-like lichenified lesions localized mostly in the lower 
extremities and extensor forearms.2   Specifically in EB pruriginosa, 13 mutations, 9 of 
which involve glycine substitution, have been reported in literature (Fig. 2).  
Here, we have identified a two-generation EB pruriginosa kindred of Taiwanese 
descent (Fig. 1a).  The proband is a 52-year old woman (II-8) who developed intense 
pruritic blisters in her lower extremities and extensor surface of both arms in her twenties.    
A detailed clinical description of her symptoms was reported previously in the Chinese 
literature.13   Briefly, histology of biopsy showed a subepidermal cleft and mild 
perivascular mononuclear infiltration in the upper dermis.  Upon electron microscopic 
examination, the anchoring fibrils were found to be decreased in number and thinner than in 
normal control skin.  Neither the parents nor the six other siblings of the index case 
developed any similar symptoms.  Recently, at the age of 25 years, the son (III-1) of the 
proband developed similar pruritic blisters on both shins and extensor arms (Fig. 2b).  
Although the 22 year-old daughter of the proband (III-2) lacked blistering lesions, nail 
dystrophy, and other symptoms of the disease, she had reported localized pruritus on 
pretibial skin and not yet reached the age of onset of her mother and brother.
 After obtaining informed consent, DNA was isolated from peripheral blood 
lymphocytes in individuals II-7, II-8, and III-1 and from buccal cells in individual III-2, 
using PureGene DNA Isolation Kit (Minneapolis, MN).  PCR amplification of the 
genomic sequence of COL7A1 gene was performed with oligonucleotide primers and 
conditions described previously.6   The PCR products were directly sequenced using ABI 
Prism Big Dye Terminator Cycle Sequencing Ready Reaction kit (Applied Biosystems) 
and the ABI Prism 310 automated sequencing system.  Sequencing of affected individuals 
(II-8 and III-1) revealed a heterozygous GT transversion in exon 92 of the COL7A1 gene at 
nucleotide position 7097 (Fig. 1c), leading to the conversion of a glycine residue (GGT) to 
a valine residue (GTT), designated G2366V.  Although individual III-2 has not yet 
developed the blistering symptoms of EB pruriginosa, sequence analysis confirmed that she 
is a carrier of the missense mutation and thus predisposed to developing symptoms in the 
future.  Mismatched PCR with a forward primer (5’-GAGCTC CTG TGA GCC AAT 
TC-3’) and a reverse mismatch primer (5’-CTG GGT ACA CAT ACC TTG TAA-3’) was 
used to create a new recognition site for the restriction enzyme MaeIII.  Restriction digest 
of the mismatched PCR product confirmed the mutation in affected and carrier family 
members, and excluded the mutation from 33 unrelated, unaffected control individuals, thus 
arguing against it being a common polymorphism.
To date, the etiology of severe pruritus in EB pruriginosa is unknown.  Several 
studies had implicated an elevated IgE level and immune predisposition to atopy in the 
pathogenesis of the pruriginosa phenotype.4,15   Interestingly, with no prior personal or 
family history of atopy, patient III-1 reported an episode of idiopathic atopic dermatitis in 
the extensor arms, waist, buttock, and pretibial areas immediately before the appearance of 
blisters on his pretibia.  In accounting for pruritus in the family reported here, available 
blood chemistry of patient III-1 showed an elevated level of serum IgE (222 IU/milliliter; 
normal range 0-59 IU/milliliter), over three times the upper limit of normal range.  Other 
causes of itching in III-1 have been ruled out, including thyroid dysfunction, uremia, and 
low ferritin levels.  Our study supports the earlier observation by Mellerio et al4 which 
found serum IgE levels to be elevated in seven out of nine EB pruriginosa patients.  The 
pathogenesis of pruriginosa phenotype is poorly understood and how the immune response 
may participate in the development of the phenotype remains to be elucidated.
The mutation in residue G2366 occurs in the midst of 17 consecutive uninterrupted 
Gly-X-Y repeats in the triple helical domain of  COL7A1.  The missense mutation 
G2366V would likely destabilize the essential triple-helix formation of the collagenous 
domain.  Glycine substitution mutations have been previously reported in various subtypes 
of DDEB, including the Pasini, Cockayne-Touraine,  pretibial, and pruriginosa  subtypes.
3,4,8-10  Interestingly, in the glycine residue 2366, one compound heterozygous patient 
with G2366S/G2063W mutations was diagnosed with recessive dystrophic EB,14 
highlighting the importance of residue G2366 (Fig. 2).  Similarly, a heterozygous glycine-
to-serine missense mutation (G2369S) in the adjacent Gly-X-Y repeat causes dominant EB 
pruriginosa (Fig. 2).4   This observation is consistent with the notion that the specific 
position of a glycine substitution within a particular helical block, rather than its position 
along the entire collagenous domain, might be more critical in determining its impact on the 
overall stability of the collagen protein, disease phenotype, and mode of inheritance.3  
In summary, we report the identification of a novel missense mutation, G2366V, 
within a Gly-X-Y repeat of type VII collagen in a family diagnosed with epidermolysis 
bullosa pruriginosa.  This result furthers our understanding of both the clinical and allelic 
heterogeneity displayed in this subtype of DDEB and extends the body of evidence 
implicating COL7A1 gene mutations in epidermolysis bullosa pruriginosa.
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Legends for Figures
Figure 1  (a) Pedigree of a Taiwanese family with epidermolysis bullosa pruriginosa.  
Affected individuals are indicated by filled figures. (b) Clinical appearance of individual 
III-1 showing clusters of vesicles and prurigo-like nodules on bilateral pretibial skin.  (c) 
DNA sequence from an unrelated, unaffected control individual and an affected individual 
(II-8) are shown.  The arrows indicate nucleotide position 7097, which is mutated from G-
to-T in the heterozygous sequence of affected and carrier individuals, resulting in the 
missense mutation G2366V.
Figure 2   Compilation of mutations in COL7A1 resulting in EB pruriginosa (modified 
from Mellerio et al, 1999).  G2366V described in this study is shown in bold.  G1791E, 
5532+1GA/7786delG, G2242R, 6863del16, G2369S, and G2713R (Mellerio et al, 1999); 
G2239D and G2242E (Tamai et al, 1998); G2037E (Jonkman et al, 1998); G2034R (Chen 
et al, 2000); G2028R (Murata et al, 2000), and 6899AG (Jiang et al, 2002).  Compound 
heterozygote G2366S/G2063W resulted in recessive dystrophic epidermolysis bullosa 
(Hashimoto et al, 1999). 


